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Concatemers of various numbers of the third ligand binding repeat of human very-low density lipoprotein receptor arranged in tandem
were fused to maltose-binding protein and expressed as soluble polypeptides. These artificial receptors protected HeLa cells against infection
with human rhinovirus serotype 2 (HRV2) to a degree that strongly increased with the number of repeats present; maximal protection was
seen for the pentameric concatemer (MBP-V33333). This V3 pentamer neutralized HRV2 more efficiently than a recombinant protein with
the entire ligand binding domain of the native receptor encompassing all 8 non-identical repeats. A concatemer of seven V3 modules (MBP-
V3333333) was also less neutralizing. Neutralization was correlated with the degree of inhibition of virus binding to the cell surface. The
results were in agreement with kinetic measurements using Biacore instrumentation demonstrating an increase in avidity with the number of
modules present. At low concentrations of the receptor fragments, a 1:1 Langmuir kinetics was observed which became of complex type in
the higher concentration range. This is most likely a consequence of receptor molecules simultaneously binding via several modules. Since
there is no viral aggregation, neutralization of viral infectivity results from blockage of the receptor binding sites and possibly from inhibition
of viral uncoating by crosslinking the viral capsid subunits via multi-module binding. Finally, the low affinity of the single V3 module
allowed demonstrating the possibility of mapping the binding epitope of the V3 receptor fragment by saturation transfer difference nuclear
magnetic resonance methodology.
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Human rhinoviruses (HRVs) are responsible for about
50% of all mild respiratory infections, essentially manifest-
ing by a running nose (Couch, 1996). They are small
positive sense single-stranded RNA viruses sharing the0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.05.016
* Corresponding author. Fax: +43 1 4277 9616.
E-mail address: dieter.blaas@meduniwien.ac.at (D. Blaas).
1 Current address: Biomin Gesunde Tiererna¨hrung International GmbH,
3130 Herzogenburg, Austria.
2 Current address: Zentrum f u¨r Anatomie und Zellbiologie, Medical
University Vienna, Austria.icosahedral capsid architecture and overall genome organ-
ization with other picornaviruses such as the polio- and
coxsackieviruses, serious human pathogens. The RNA
genome is roughly 7100 nucleotides in length and encodes
a polyprotein that is co-translationally and autocatalytically
processed into the four capsid proteins VP1, VP2, VP3, and
VP4, and several non-structural proteins taking part in
replication (for review on picornaviruses see (Semler and
Wimmer, 2002)). For cell entry, 87 HRV serotypes use
intercellular adhesion molecule 1 (ICAM-1), and 12
serotypes use members of the low density lipoprotein
receptor (LDLR) family (Ledford et al., 2004; Vlasak et05) 259 – 269
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the available three-dimensional structures of the capsid
proteins only, the principle underlying the distinction
between the receptors could not be elucidated.
The ligand binding domain at the N-terminus of LDL-
receptors is made up of several imperfect direct repeats, each
about 40 amino acid residues in length. Each of the modules
is stabilized by a Ca++ ion and three disulfide bonds. The
low-density lipoprotein receptor (LDLR), the very-low
density lipoprotein receptor (VLDLR), and the LDLR-
related protein (LRP) contain 7, 8, and 31 such repeats (for
review see (Strickland et al., 1995)). The ligand binding
region is succeeded by a domain with similarity to the
epidermal growth factor precursor interspaced with YWTD
repeats. At least in LDLR, this part of the molecule adopts
the conformation of a ß-propeller. At low pH, as it prevails in
endosomes, the ligand binding domain folds back and
interacts with this ß-propeller whereby bound ligands are
out-competed (Rudenko et al., 2002). Proximal to the
membrane is a more or less O-glycosylated region that is
followed by the transmembrane domain and a cytoplasmic
tail with NPXY motives responsible for clathrin-dependent
internalization (Snyers et al., 2003).
Receptor derivatives have been envisaged as antivirals
acting via competition for cellular binding sites; e.g., soluble
ICAM-1 and bi- or penta-dentate ICAM-1-IgG, IgA, and
IgM-fusion proteins have been shown to efficiently inhibit
major group rhinovirus infection in vitro (Crump et al.,
1993; Marlin et al., 1990; Martin et al., 1993; Ohlin et al.,
1994) and in vivo (Shigeta, 1998). In the case of ICAM-1,
this inhibition is not only due to competition with the
cellular receptor but also to a catalytic, virus-neutralizing
function; binding to the viral canyon, a cleft encircling the
five-fold axes of icosahedral symmetry, promotes structural
modifications resulting in RNA release (Nurani et al., 2003).
Pursuing similar lines of research on minor group viruses,
we have shown previously that preincubation of HRV2 with
a selection of recombinant soluble LDLR or VLDLR
derivatives also protects HeLa cells against infection
(Marlovits et al., 1998a, 1998b, 1998c; Ronacher et al.,
2000; Verdaguer et al., 2004). However, in contrast to
ICAM-1, where only the tip of the N-terminal domain
interacts with the virus, we recently presented evidence that
repeat 5 together with repeat 1 and/or 2 of LDLR play a role
in binding HRV1A. This suggests the possibility of multi-
module attachment (Herdy et al., 2004).
Reconstruction of cryo-electron microscopy (cryo-EM)
images from complexes between virus and a VLDLR
fragment containing repeats 1 to 3 only (V123) allowed
mapping of the binding site to the BC and HI surface loops of
the capsid protein VP1 (Hewat et al., 2000). In a follow up
study, a number of recombinant proteins with different
combinations of the ligand binding repeats were used for
complex formation and structure analysis by cryo-EM
suggested that two consecutive modules were simultaneously
bound to two non-identical sites on the symmetry relatedsubunits of the viral capsid. Conversely, in the case of
minireceptors composed of two repeats (e.g., the maltose-
binding protein fusions of V23 and V33, i.e., MBP-V23 and
MBP-V33), only a single repeat was found to contact the viral
surface whereas the other one was disordered. This might be
caused by the MBP presumably hindering attachment of the
neighboring repeat (Neumann et al., 2003). However, there
was no evidence for multivalent binding to identical sites and
all available structural data suggested that VLDLR fragments
with more than two modules attached via repeat 3 (with a
possible minor contribution of repeat 2) but with no
participation of the other repeats. During these studies, we
observed substantial differences between the various receptor
fragments with respect to their cell-protecting, virus neutral-
izing capacity. As our experiments also revealed that single
repeats were virtually not neutralizing, we wondered whether
artificial combinations of the modules would possibly attach
in an ordered, multivalent fashion and thereby bind the virus
with higher avidity. Therefore, we expressed various con-
catemers of V3 and assessed their attachment to HRV2 and
their capacity to inhibit viral infection. We here show that
the neutralizing activity is greatly enhanced upon concate-
nation. The activity was maximal for MBP-V33333 but
decreased upon concatenation of seven copies of V3. The
results suggest that MBP-V33333 adopts a conformation
particularly favorable for attachment to the virus and thereby
to prevent its binding to the cellular receptors.Results
HRV2 binds membrane-immobilized receptor fragments in
virus overlay blots
Concatemers of repeat 3 were expressed in bacteria as
fusion proteins with MBP, refolded, purified, and similar
amounts of the proteins were run under non-reducing
conditions on a SDS-polyacrylamide gel. Proteins were
electrotransferred to a PVDF membrane, and after blocking,
receptors were revealed by using antibodies against LDLR.
As seen in Fig. 1, upper panel, the receptor fragments were
present at similar amounts and migrated in the gel as
monomers; only in case of MBP-V33 a doublet and in case
of MBP-V333 two weak bands of higher molecular mass
were seen. They might represent products of aberrant folding
or dimerization. As the higherMr material also yielded bands
with radiolabeled virus, the binding activity was not grossly
impaired by these modifications. In the case of MBP-V333,
the interaction with the virus appears even somewhat
increased upon aggregation (compare amounts of monomer
and presumed dimer of MBP-V333 with their virus binding
activity, top and bottom panel in Fig. 1). MBP, used as a
negative control, did not react with the antibodies.
Receptor associated protein (RAP) a specific chaperone,
binds strongly to VLDLR and LRP and has been frequently
used as an inhibitor of ligand binding (Bu et al., 1995). For
Fig. 1. Concatemers of repeat 3 of VLDLR bind HRV2. The concatemers
indicated (‘‘MBP’’ is omitted for simplicity) were run on a SDS 10% poly-
acrylamide gel under non-reducing conditions and transferred to a PDVF
membrane. After blocking, the membrane was incubated with anti-VLDLR
IgY (upper panel), with biotin-conjugated GST-RAP (middle panel), and with
30,000 cpm of [35S]-methionine labeled HRV2 (lower panel). Detection was
with HRP-conjugated anti-chicken IgY or with HRP-conjugated streptavidin
followed by substrate, and by exposure to X-ray film, respectively.
Fig. 2. MBP-fusions with concatemers of repeat 3 of VLDLR protect HeLa
cells against infection with HRV2. Serial two-fold dilutions of the receptor
constructs were incubated with 100 TCID50 of HRV2 for 60 min at room
temperature and the mixture was applied onto HeLa cell monolayers grown
in microtiter wells. After incubation at 34 -C for 3 days, cells remaining
attached to the plastic were stained with crystal violet.
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correctly folded, a glutathione-S-transferase-RAP fusion
protein (GST-RAP) was used to assess binding (Fig. 1,
middle panel). In accordance with earlier data (Mikhailenko
et al., 1999), GST-RAP failed to bind to the single repeat
(MBP-V3) whereas it bound to all other fragments, although
weakly to MBP-V33. MBP, cleaved from the fusion protein
MBP-V33333 with factor Xa and collected in the flow
through of a Ni-NTA column that retains the hexa-his
tagged receptor-moiety, was used as control and showed
only some very faint bands. These most probably originated
from incompletely cleaved and partially degraded MBP-
V33333 that had lost the hexa-his tag and was thus present
in the sample at low amounts (Ronacher et al., 2000).
Virus binding activity was then assessed by incubation
with [35S]-labeled HRV2 followed by autoradiography. As
seen in Fig. 1, lower panel, all concatemers of V3 bound
HRV2; virus binding was comparable to that of receptors
with the natural sequence of the repeats (compare MBP-V33
to MBP-V23 and MBP-V333 to MBP-V123). Only for
MBP-V3, no virus binding was seen in this assay although
its amount was similar to that of the other receptors as
judged from Coomassie brilliant blue staining (not shown)
and immunoblotting with VLDLR specific antiserum (Fig.
1, upper panel). Note that the difference in migration of theproteins is small due to the contribution of only 6.9 kDa of a
single V3 module to the Mr of MBP (42.3 kDa).
V3-concatemers protect HeLa cells against infection by
HRV2
The capacity of various VLDLR receptor constructs to
neutralize infection of HeLa cells by HRV2 was then
assessed. Two-fold serial dilutions of the purified conca-
temers were incubated for 30 min at room temperature with
100 TCID50 of HRV2. The mixtures were then transferred
onto monolayers of HeLa cells grown in 96-well plates and
the infection was allowed to proceed for 3 days. In this assay,
the absence of cell lysis (as detected by crystal violet staining
of intact cells) indicates complete neutralization of the virus
by the soluble receptors. Partial neutralization also leads to
complete lysis of the culture because even few newly
produced virions spread and infect other cells during
incubation for 3 days. Soluble ‘‘natural’’ VLDLR minire-
ceptors encompassing repeats 1 to 3 (MBP-V123) and 1 to 8
(MBP-V12345678) were included for comparison. Fig. 2
illustrates that MBP-V33333 protects HeLa cells most
efficiently against viral infection. On a molar basis, it was
about 250 (28) times more efficient (i.e., 250 times less
MBP-V33333 was required for neutralization) than MBP-
V123 in this assay. On the other hand, the neutralization
efficiency of MBP-V33 was much lower than that of MBP-
V123 and just concentrations exceeding 32 nmol/l led to cell
protection (data not shown but see also (Verdaguer et al.,
2004)). This might indicate that the first repeat after the MBP
contributes much less to binding, presumably because of
steric problems caused by the MBP (Neumann et al., 2003;
Ronacher et al., 2000; Verdaguer et al., 2004). The fragment
containing three repeats, MBP-V333, was only slightly more
neutralizing than MBP-V123 and slightly less than MBP-
V1–8. However, virus neutralization by MBP-V3333 and
MBP-V33333 was at least 20 times higher as compared to
the entire native ligand binding domain. MBP-V3333333,
Fig. 3. Concatemers of V3 protect a mouse fibroblast cell line expressing
human LDLR against HRV2 infection by inhibition of virus binding. (A)
HRV2L was preincubated with the concentrations of MBP-V123 or MBP-
V33333 indicated for 1 h at room temperature and transferred onto M4-
LDLR cells grown on coverslips. Cells were washed and further incubated
in infection medium. The next day, virus-infected cells were identified upon
staining viral antigens with mAb 8F5 and secondary FITC-conjugated
antibody. Cells producing viral antigen were counted under the fluorescence
microscope as described in Materials and methods. The number of cells
infected in the presence of the receptors is presented as percentage of the
number of cells infected in the absence of receptor. Each point corresponds
to the mean of two independent experiments with indicated span. (B)
Radiolabeled HRV2 (¨10,000 cpm) was preincubated with the receptors
for 30 min at room temperature and the mixture was transferred onto
subconfluent M4-LDLR806 cells grown in 24-well plates. After 30 min at
room temperature, the cells were washed 3 times and cell associated
radioactivity was determined by liquid scintillation counting. Each point
represents the mean of duplicate measurements with indicated span.
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V12345678; this might be taken to indicate that this receptor
is too big to allow for an ordered attachment; possibly, it
prevents other soluble receptors from binding but also leaves
some sites accessible for cell surface attachment. Cryo-EM
of complexes between this receptor and HRV2 showed no
evidence for aggregation (Neumann et al., 2003). This
indicates that the additional repeats are not available for
binding another virus particle and that neutralization is most
probably based on blockage of the binding sites.
Soluble receptors reduce the number of cells becoming
infected upon viral challenge
To examine more accurately the concentration depend-
ence of the neutralization of HRV2 by the various VLDLR
fragments, we counted the number of virus-producing cells
in the presence of the soluble mini-receptors 1 day after
infection. For this experiment, M4-LDLR cells were used.
This is a murine LDLR/ and LRP/ cell line that has
been stably transfected to express human LDLR (Reith-
mayer et al., 2002). These cells were selected because they
have the capacity, although limited, to replicate a mouse
adapted HRV2 (HRV2L; (Yin and Lomax, 1983)) but are not
readily lysed by the virus. This allows for monitoring the
infection by counting the number of cells actively replicat-
ing the virus after staining for virus-specific proteins.
M4-LDLR cells were seeded on coverslips and infected
with HRV2L at anMOI of 10. TheMOI was chosen such as to
allow for counting virus-producing cells under the micro-
scope 1 day after infection by using immunofluorescence
microscopy detection with the monoclonal anti-HRV2 anti-
body 8F5 (Skern et al., 1987) followed by FITC-conjugated
anti-mouse antibody. The virus was pre-incubated with
increasing concentrations of the MBP-VLDLR fragments
prior to challenging the cells. As control, virus was incubated
without receptor. Only MBP-V33333 and MBP-V123,
exhibiting a strong difference in the neutralization capacity
(see Fig. 2), were used in this experiment. Fig. 3A shows the
ratio between the number of cells infected in the presence of
the soluble receptors and the number of cells infected in their
absence. For MBP-V123-mediated neutralization of HRV2L,
the number of infected cells decreased gradually upon
increasing the concentration of receptor. However, the curve
only asymptotically approached zero infected cells suggest-
ing that receptor concentrations largely exceeding 30 nmol/l
would be needed to fully protect the cells (i.e., that none of the
cells becomes infected). In contrast, complete neutralization
was readily achieved byMBP-V33333. Not a single infected
cell was seen at 7 nmol/l of MBP-V33333, whereas in the
presence of MBP-V123 at 30 nmol/l (and even at 60 nmol/l;
not shown) some few cells clearly showed viral protein
synthesis. These results are consistent with the neutraliza-
tion data shown in Fig. 2, where, on a molar basis, ¨250
times (28) more MBP-V123 than MBP-V33333 was needed
to fully protect the cells.Virus binding is inhibited by recombinant receptor
fragments
Viral infectivity can be inhibited by agents (i) competing
with the cellular receptor for viral binding sites, (ii) by
prevention of uncoating (i.e., RNA release), (iii) by
inactivation of the virus (e.g., as occurs upon binding of
ICAM-1 to some major group HRVs; this receptor binds
into the viral canyon and is believed to push apart the
subunits like a wedge or to hold them in a more open
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mately leading to uncoating (Xing et al., 2003), or (iv) by
aggregation. Having ruled out the latter two possibilities
(see above and (Hofer et al., 1994)), we wondered to what
extent cell binding of radioactively labeled HRV2 was
inhibited by the VLDLR fragments. For this experiment,
M4-LDLR806 cells were employed. These cells stably
express a truncated version of human LDLR lacking 33
amino acid residues in the cytoplasmic domain including the
coated pit localization signal. They express high amounts of
LDLR on the plasma membrane and therefore have a high
virus-binding capacity (Reithmayer et al., 2002; Snyers et
al., 2003). Metabolically labeled [35S]-HRV2 was incubated
with increasing concentrations of MBP-V123 or of MBP-
V33333 for 30 min at room temperature. The mixtures were
then transferred onto the cells and the incubation was
continued for 30 min. After washing three times, the cells
were lysed and cell-associated radioactivity was determined
by scintillation counting. Like for the neutralization of
infectivity, virus binding (and internalization that also
occurs under these conditions) was found to be prevented
by much lower concentrations of MBP-V33333 as com-
pared to MBP-V123 (Fig. 3B). Similarly to the lack of a
complete block of infection (Fig. 3A), even at the highest
concentration, MBP-V123 did not completely abrogate
virus binding, whereas very low concentrations of MBP-
V33333 completely prevented attachment of the virus. The
difference between the two fragments with respect to their
capacity to block virus binding was even more accentuated
than in the neutralization assay (Fig. 3A). Curve fitting to
the hyperbolic function B ¼ Bmax  Bmax  Bminð Þ R½
Hill
KHill
D
þ R½ Hill where B
is bound receptor, R is receptor concentration, and Hill is the
Hill coefficient yielded a KD of 1.6 nmol/l for MBP-V123
and a KD of 0.4 nmol/l for MBP-V33333 clearly indicating
stronger binding of the latter concatemer. Interestingly, the
Hill coefficient was about 1 for MBP-V123 and about 6 for
MBP-V33333. This might be due to strong cooperativity of
the modules in the pentamer suggesting that binding of one
repeat facilitates binding of the others. Taken together, these
results suggest that neutralization of HRV2-infection by the
VLDLR-derived fragments is, at least to a large part, due to
inhibition of binding of the virus to the cellular receptors.
They further suggest that MBP-V33333 readily covers all
receptor binding sites, whereas binding of MBP-V123 even
at the highest concentration tested leaves some sites on the
viral surface available for binding of cell surface receptors.
However, the observed effect might also only be due to the
considerable differences in affinity/avidity and the strong
cooperativity observed for MBP-V33333.
Kinetic parameters of the HRV2-receptor interaction
In order to assess whether the inhibitory activity of the
receptor derivates was correlated with their affinity/avidity
for the virus, the kinetic parameters of the binding reaction
were determined using a Biacore apparatus. Determinationof the binding kinetics requires the virus to be immobilized
on the sensor chip. The receptor is then injected in a
constant flow over this modified surface. Binding leads to
an increase of the mass at the surface of the chip which is
translated into a signal expressed as resonance units (RU).
Dissociation of the bound receptor occurs as soon as plain
buffer solution is being passed over the surface. After each
association–dissociation cycle, any residual receptor has to
be completely detached for the signal to return to the
baseline. This is usually brought about by flushing with low
pH buffer and complete detachment of the receptors in
Biacore experiments with HRV3 and with ECHO11, other
picornaviruses, was achieved in this way (Casasnovas and
Springer, 1995; Lea et al., 1998). However, in our case,
using the same conditions, the receptor was not removed
and pH values below 5.6 denatured HRV2, preventing re-
use of the chip ((Gruenberger et al., 1991) and data not
shown). Therefore, we chose to use a sandwich type of
assembly by covalently immobilizing MBP-V33333 at high
density followed by attachment of HRV2. A similar
sandwich method has been used previously for the
determination of the parameters underlying antibody bind-
ing to Semliki forest virus (Hammar et al., 2003). Initial
experiments showed that virus became tightly bound to the
surface carrying MBP-V33333 and was not dissociated even
upon washing with buffer for several hours (not shown).
Most probably, this is not only due to high avidity
(functional affinity) of MBP-V33333 for the virus but also
to attachment of the virion via several receptor molecules.
For regeneration, virus, together with any residual receptor
remaining after the dissociation phase, was detached with
low pH buffer and new virus was bound to the chip-
immobilized receptor for the next association–dissociation
cycle. The sandwich also exploits the high specificity of the
receptor to only bind native virus and no subviral particles.
Such particles might be present in the preparation since they
are intermediates of the uncoating process. ‘‘A-particles’’
have lost the innermost capsid protein VP4, whereas ‘‘B-
particles’’ have additionally lost the genomic RNA (Lonberg
Holm and Noble Harvey, 1973).
In a first set of experiments solutions of MBP-V123 at
concentrations between 4 nM and 200 nM were added to the
flow over HRV2 immobilized to the chip-bound MBP-
V33333. The tracings showed typical association–dissoci-
ation curves (Fig. 4A, gray traces). However, attempts to
determine the kinetic parameters of the reaction with the
BiaEvaluation software using the ‘‘global fit’’ procedure that
simultaneously fits association and dissociation rate con-
stants, kon and koff, at varying receptor concentrations
revealed that neither of the available models was able to
fit the curves satisfactorily. For example, the simple 1:1
Langmuir model yielded a very poor fit, and meaningful
kinetic parameters could not be derived (see dashed lines in
Fig. 4A). All attempts to arrive at acceptable fits by using
more complex binding models also failed (data not shown).
Therefore, we tried to analyze the data by individually fitting
Fig. 4. Kinetics of receptor binding to HRV2 as determined by surface
plasmon resonance. HRV2 was attached non-covalently to MBP-V33333
immobilized to F1 chips. (A) MBP-V123 was then added to the flow at the
concentrations shown to monitor the binding phase. Then, only buffer was
run over the chip to monitor the dissociation phase. After each measure-
ment, the surface was regenerated by removing residual bound receptor
together with the virus by rinsing with low pH buffer and new virus was
bound to the immobilized receptor. Data were only included in the analysis
when the amount of attached virus was similar. The final data set was
subjected to the ‘‘Global Fit’’ procedure using the 1:1 Langmuir model and
the ‘‘Heterogenous Ligand’’ model as provided in the BiaEvaluation
software. (B and C) Langmuir 1:1 fit of the binding and dissociation of
MBP-V3333333 at 100 nM (B) and at 1 nM (C) demonstrating the good fit
in the low but the bad fit in the high concentration range. Measured data,
thick grey lines; fit data, dashed black lines.
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koff. This revealed interesting differences between curves at
high and low receptor concentrations (exemplified for MBP-
V3333333 in Figs. 4B and C). For higher concentrations, the
fits were poor. However, when the lowest concentrations
were utilized the simple (1:1) binding model yielded almost
excellent fits (compare Figs. 4B and C; 100 nM and 1 nM
receptor concentration). The quality of the fit is also
reflected in high and low v2 values, respectively. A slight
improvement at the higher concentrations was seen when
invoking a more complex binding model such as the
heterogeneous ligand model that, in this particular case,
assumes the presence of two different binding sites on the
immobilized virus (top and bottom panels in Fig. 4B). On
the other hand, at 1 nM receptor concentration the fit was not
improved any further by applying a two-site heterogeneous
ligand binding model (top and bottom panels in Fig. 4C).
Similar results were obtained for the other concatemers (not
shown). For these reasons, only the binding curves at the
lowest concentrations were analyzed using a simple Lang-
muir (1:1) binding model except for MBP-V123, where the
‘‘two site heterogeneous ligand model’’ gave a better fit. The
v2 values were generally below 0.1. Table 1 shows that the
measured affinity of the various receptor concatemers
increases with the number of V3 copies present until
MBP-V33333, where the affinity is apparently too high to
be measurable by this method. In accordance with the
neutralization data, it does not further increase upon addition
of two more V3 repeats but rather decreases. Receptors with
the natural sequence of modules (i.e., MBP-V12345678 and
MBP-V123) display intermediate and low affinities, respec-
tively, as compared to the concatemers of module 3.
STD NMR experiments to study the binding of receptor
fragments
Over the past few years, the STD NMR technique
(Mayer and Meyer, 2001) has become very popular (for a
review, see (Meyer and Peters, 2003)). The technique allows
to rapidly identify binding ligands from mixtures, and, more
importantly, yields structural information on ligand binding
epitopes at atomic resolution (Mayer and Meyer, 2001).
Recently, we have shown that it is possible to detect and
characterize the binding of small organic molecules to the
hydrophobic pocket of the virus (Benie et al., 2003).
Therefore, we wondered whether this technique would be
applicable to study the binding of VLDLR receptor
fragments to HRV2. The STD NMR technique requires
one binding partner to be small as compared to the other, a
condition which is met by the receptor (7 kDa per module)
and the virus (8 MDa). The kinetics of the interaction
between the larger concatemers and the virus, as determined
by surface plasmon resonance (see Table 1), is far too slow
for STD NMR experiments. Therefore, we chose the single
repeat V3 for initial NMR experiments. MBP was removed
from the MBP-V3 by cleavage with factor Xa (Ronacher et
Table 1
Kinetic and equilibrium binding constants for various MBP-VLDLR receptor derivatives as determined with the Biacore instrument using the ‘‘simultaneous
fit’’ method
Analyte (MBP-) kon (M
1 s1) koff (s
1) KD (mol/l) c (nmol/l) Model
V33333 n.a. n.a. <1012 1 Langmuir
V3333 2.0  106 3.2  105 1.6  1011 1 Langmuir
V3333333 3.7  106 1.1  104 3.0  1011 1 Langmuir
V12345678 1.5  106 1.8  104 1.2  1010 3 Langmuir
V333 9.2  105 3.4  104 3.7  1010 5 Langmuir
V123 8.4  106 2.2  102 1.4  108 2 Heterogeneous ligand
V3 2.2  106 5  101 4.5  107 10,000 Langmuir
Data were derived from experiments with the receptors present at concentration c. Receptor fragments are arranged in the order of decreasing functional affinity
(top to bottom). n.a. not applicable; data could not be derived because the affinity was beyond the measuring limits of the instrument.
R. Moser et al. / Virology 338 (2005) 259–269 265al., 2000) and V3 was purified via affinity chromatography
on a Ni-NTA column making use of the appended His6-tag.
A STD NMR spectrum obtained for V3 in the presence
of native virus is shown in Fig. 5, demonstrating strong STD
signals. Control experiments (see Materials and Methods)
showed that no direct irradiation of V3 occurred under the
chosen experimental conditions. It is noteworthy that an on-
resonance frequency of 4 ppm still yielded a significant
saturation of the virus 1H NMR resonances. Although a
complete chemical shift assignment is not yet available, it is
clear that the STD NMR spectrum contains the information
required to determine the binding epitope. Fig. 5 demon-
strates that different resonances of V3 receive different
amounts of saturation. These differences will be translatedFig. 5. STD NMR spectrum of V3 in the presence of HRV2. Overlaid NMR
spectra (500 MHz, 288K; dotted lines) 1D 1H NMR reference spectrum of a
mixture of HRV2 and a 500-fold excess (over binding sites) of V3, and 1D
STD NMR spectrum of the same sample (plain lines). The intensities of the
down-field spectral region (6–9.4 ppm) were expanded for better visual-
ization. The arrow indicates the signal used to match the intensities of the
reference and saturated spectrum. Up-triangles show some of the signals
receiving a larger amount of saturation. Down-triangles indicate signals
with low level of saturation in the difference spectrum. Distances between
protons in V3 and in the binding site of HRV2 can be derived from the
difference between the intensities of the STD NMR and the reference 1H
NMR signals.into a binding epitope as soon as an assignment of V3 is
available. In the present analysis, different spectral regions
of the STD spectrum were integrated (values not shown)
which enabled us to classify signals that receive high or low
amounts of saturation (up- and down-triangles, in Fig. 5).
The better resolution in the region of backbone amide and
aromatic protons (between 6.5 and 10 ppm) highlights these
differences (Fig. 5).Discussion
In this paper, we have quantified the contribution of single
modules to virus neutralization and inhibition of virus
binding by using artificial concatemers of V3, synthesized
as recombinant fusion with maltose binding protein. In virus
overlay blots, all the concatemers bound HRV2, whereas no
interaction of the single module MBP-V3 with the virus was
detected under these particular conditions. In this respect,
HRV2 resembles RAP that also requires more than one
repeat for binding to LRP, which is believed to harbor at least
two independent RAP binding sites (Mikhailenko et al.,
1999). It should be mentioned that some weak binding of
MBP-V3 to HRV2 can be detected at very high concen-
trations in overlay blots (Nizet et al., submitted for
publication) and that MBP-V3 displays marginal virus
inhibition (Verdaguer et al., 2004). The virus overlay blots
failed to reveal large differences in virus binding of the
different concatemers presumably because the receptors
were present at high concentration within the bands. In
contrast, in cell protection assays, a clear difference was seen
in serial two-fold dilutions of the receptor. Interestingly,
MBP-V33333 had the strongest cell protection capacity. It
would be interesting to know how many receptor molecules
must bind per virion to achieve neutralization. However, due
to the high and ill-defined ratio between the total number of
viral particles and infectious viral particles of between 24:1
and 240:1 (Abraham and Colonno, 1984), this value is
extremely difficult to determine.
Results of earlier experiments with complexes between
MBP-V33333 and HRV2 suggested simultaneous binding
of multiple VLDLR ligand binding repeats to the viral
surface. Virions carrying between 0 and 12 receptor
R. Moser et al. / Virology 338 (2005) 259–269266molecules could be separated by capillary electrophoresis
(Konecsni et al., 2004); in combination with the cryo-EM
(Neumann et al., 2003) and X-ray data (Verdaguer et al.,
2004), this suggested already that the receptor molecules
must have attached around the five vertices of the
icosahedron. Our present results are in complete agreement
with this model. The longer receptor MBP-V333333 or
MBP-V12345678 were less neutralizing because they might
fail to attach in an ordered fashion.
The weakly neutralizing MBP-V123 and the strongly
neutralizing MBP-V33333 were examined with respect to
inhibition of virus binding to M4-LDLR806 cells and to
neutralization of viral infection by observing de novo viral
protein synthesis on the single cell level. It turned out that
MBP-V123 did neither inhibit virus binding nor cell infection
completely even at the highest concentrations tested. Con-
versely, MBP-V33333 was extremely effective in both
respects. This might be interpreted as an incomplete coverage
of receptor binding sites by MBP-V123. Since V1 fails to
bind all together (Neumann et al., 2003) and only V2 and V3
can bind, one can envisage a situation in which two copies of
MBP-V123 cover four binding sites but leave one open for
attachment to a receptor on the cell membrane. In the case of
MBP-V33333, all potential sites might be rendered inacces-
sible, which is reflected in the virtual absence of cell binding
and infection already at low concentrations.
Kinetic measurements with Biacore instrumentation point
into the same direction and show that the functional affinity
between the various receptors is quite different. However,
whereas similar experiments with HRV3 and soluble ICAM-
1 (Casasnovas and Springer, 1995) and with ECHO11 and
soluble DAF (Lea et al., 1998) gave textbook like binding
and dissociation curves, the interaction between HRV2 and
the various soluble receptors was complex and the curves
followed simple kinetic models only at low concentrations.
Nevertheless, using only single curve fitting, kinetic
constants, and equilibrium dissociation constants could be
derived (Table 1). Whereas the strongest neutralizer MBP-
V33333 exhibited an affinity beyond the upper measuring
range of the instrument, all other receptors bound with lower
affinity and their binding parameters could be determined.
Only in case of MBP-V3 micromolar concentrations were
required to obtain an interpretable signal. Taken together,
this suggests that the geometry of MBP-V33333 is such as to
fit extremely well onto the vertex of the virion and does not
leave any binding site free. The values of the dissociation
constants were in the range of 1011 Mol/l (for MBP-V3333)
and 107 Mol/l for (MBP-V3). The complex kinetics at
higher concentrations is most probably due to simultaneous
attachment of more than one copy of the larger receptors to
the five attachment sites at the five-fold axis involving
different numbers of modules. The association rate constants
were similar for all receptor constructs and were in the order
of 106 Mol1 s1 (Table 1). Association is thus much faster
than in the case of ICAM-1 binding HRV3 (biphasic with
2450 and 135 Mol1 s1 (Casasnovas and Springer, 1995))and still faster than for decay accelerating factor (DAF)
binding Echovirus 11, another picornavirus (150,000 Mol1
s1 (Lea et al., 1998)). This probably reflects the different
exposure of the binding sites; ICAM-1 binds inside the
canyon, and DAF most probably binds ECHO 12 at the two-
fold axis in one or the other orientation that have been
determined for ECHO 7 (He et al., 2002) and ECHO 11
(Bhella et al., 2004)), respectively. Conversely, VLDR binds
to the extremely exposed star-like mesa. Furthermore, once
the first module has bound, the others certainly bind very
quickly to the neighboring sites. The dissociation rate
constants were between 3.2  105 (for MBP-V3333) and
1  101 (for MBP-V3), which indicates that dissociation
occurs more slowly the more binding repeats are present.
This resembles very much the situation of the bivalent IgG
molecules; if one of the two arms dissociates, it nevertheless
remains in the vicinity and re-binding is strongly favored as
compared to a monovalent Fab fragment (Hewat and Blaas,
2001).
The kinetic on- and off-rates of V3 lay within the range
suitable for epitope mapping via STD NMR. We thus
assessed the possibility to investigate the binding of the
VLDLR receptor to HRV2 and to determine its binding
epitopes via this technique. The pilot experiments described
here unambiguously demonstrate that it is indeed possible to
obtain high quality STD NMR spectra that contain all the
information required to define the binding epitope on the
receptor (Fig. 5). The assignment of the 1H NMR spectrum
of V3 is underway and a more detailed NMR analysis will
be published elsewhere. This is the first time that STD NMR
experiments were applied to a system consisting of a native
virus and a receptor fragment of Mr 7.3 kDa. This is
remarkable as STD NMR is usually employed for the
characterization of the binding of small ligands, i.e., with a
molecular weight below 2 kDa, to large receptor proteins.
Thus, this is a key experiment paving the way for the rapid
characterization of the interaction between a multitude of
receptor modules and various HRV serotypes at atomic
resolution.
The multi-module attachment identified here accounts for
the considerable increase in neutralization potency and
binding strength of receptor concatemers with the number of
modules present. It also tentatively explains how the
different minor group HRV serotypes bind to their host
cells; the various modules present in the natural receptors
might exhibit different affinities versus the twelve serotypes
which is compensated by the simultaneous attachment via
several modules as exemplified by HRV1A binding very
weakly to human LDLR but strongly to human LRP (Herdy
et al., 2004).
Antibodies and receptors may have overlapping but not
identical binding sites. The multitude of slightly different
receptor modules (7 in LDLR, 8 in VLDLR, and 31 in LRP)
presumably cope more easily with changes at the virus
surface occurring upon escape from neutralizing antibodies
in that reduction of binding affinity for one given module
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module.Materials and methods
Construction, expression, and purification of the V3
concatemers
The construction of MBP-V123 (maltose binding protein
fused to repeats 1, 2, and 3 of the ligand-binding domain of
human VLDLR) was described previously (Ronacher et al.,
2000). MBP–concatemer fusions containing various num-
bers of repeat 3 (V3) were prepared essentially as described
(Konecsni et al., 2004). Briefly, V3 was first amplified from a
plasmid containing the entire sequence of human VLDLR
(Marlovits et al., 1998b; Sakai et al., 1994) using primers 5V-
ATGCGGATCCAACATGCCGCATACATG and 5V-
GCAGCCCGGGACTCATATGGCACTGTTC and intro-
duced into the vector pMalc2b using restriction sites BamHI
and XmaI. The resulting plasmid encodes V3 (amino acid
residues 112 to 151 of the VLDLR precursor sequence
(Swissprot entry P98155) fused at its N-terminus to MBP via
a linker of 11 amino acid residues and at its C-terminus to a
hexa-histidine tag. The plasmid was cleaved with SmaI to
generate blunt ends immediately in 3V of the V3 sequence.
Another V3-coding sequence was made by PCR using
primers 5V-GGGACATGCCGCATACATGAAATC and 5V-
ATTGCCACAGTTTTCTTCATC and Pfu DNA polymer-
ase. This fragment was ligated into the SmaI site. After
transformation, colonies containing plasmid pMal with 1, 2,
3, or 4 copies of V3 fused toMBPwere obtained. To generate
longer concatemers, a plasmid containing MBP-V3333 was
cut with SmaI and ligated with the same PCR fragment. This
gave rise to additional concatemers with 5 and 7 copies of V3
fused to MBP. Expression, purification, and refolding were
carried out essentially as described previously with the
exception that the GST-RAP column material was not used
to promote the folding reaction (Ronacher et al., 2000).
Ligand binding assay
Receptors were separated on a SDS 10% polyacrylamide
gel under non-reducing conditions (Marlovits et al., 1998b)
and electrotransferred to a PVDF membrane. The membrane
was blocked with Tris-buffered saline (TBS) containing 2%
non-fat dried milk and 2% bovine serum albumin (blocking
buffer) for 1 h, and incubated with HRV2 metabolically
labeled with [35S]-methionine/cysteine (Neubauer et al.,
1987) for 1 h at room temperature. The membrane was
washed with blocking buffer, dried and exposed to X-ray
film. Glutathione-S-transferase fused receptor associated
protein (GST-RAP) was produced as described (Herz et al.,
1991). For immunological detection, an IgY fraction
prepared from eggs of a chicken immunized with recombi-
nant human VLDLR was used.Cell protection assay
HeLa-H1 cells (Flow Laboratories) were seeded in 96
well plates and grown to about 90% confluence in minimal
essential medium (MEM) containing 10% fetal calf serum,
100 U/ml penicillin, 100 Ag/ml streptomycin, and 2 mM l-
glutamine. HRV2, at 100 TCID50 (Blake and O’Connell,
1993), was incubated with serial two-fold dilutions of the
receptor fragments in infection medium (as above but
containing 2% fetal calf serum and 30 mM MgCl2) for 30
min at room temperature prior to challenge of the cells.
Upon incubation for 3 days at 34 -C, cells remaining
attached to the plastic were stained with crystal violet (0.1%
in water) and photographed. For the single cell protection
assay, equal numbers of M4 cells, transfected to stably
express human LDLR (M4-LDLR), were seeded on cover-
slips. They were infected at 34 -C for 20 min with HRV2L
(MOI = 10) which had been pre-incubated for 1 h with
increasing amounts of the soluble receptors. After washing
away excess virus, cells were incubated in culture medium
until the next day; virus producing cells were then detected
by indirect immunofluorescence microscopy (Snyers et al.,
2003) using the monoclonal antibody 8F5 directed against a
sequential epitope on VP2 of HRV2 (Skern et al., 1987).
Cells strongly stained in at least 25 different and randomly
chosen fields were counted under the microscope for each
receptor concentration, giving an average of successfully
infected cells. This number was related to the number of
cells producing virus in the absence of soluble receptor
which was set to 100% (i.e., no neutralization). The
experiment was performed two times.
Inhibition of binding of radioactively labeled HRV2
Equal numbers of M4 cells stably expressing a truncated
version of human LDLR lacking the last 33 amino acid
residues of the cytoplasmic tail including the clathrin
localization signal (M4-LDLR806 cells) were seeded in
24-well plates. [35S]-labeled HRV2 (¨10,000 cpm) was
mixed with increasing amounts of the soluble receptors, as
in the cell protection assay, and incubated for 30 min at
room temperature. The mixture was then transferred onto
the cells and left for 30 min at room temperature. After
washing three times with PBS, the cell-associated radio-
activity was determined by liquid scintillation counting.
Note that the amount of virus used in this experiment was
almost the same as for the cell protection assay of M4-
LDLR cells, as determined from the TCID50 of the
radioactive virus.
Kinetic measurements
Kinetic rate constants were determined on a Biacore
3000 instrument (Biacore International AB, Switzerland)
using F1 chips manufactured by the same company
following standard protocols for surface plasmon resonance
R. Moser et al. / Virology 338 (2005) 259–269268methodology (Lee et al., 2005). For assembly of the
receptor-virus sandwich, MBP-V33333 at 150 Ag/ml was
immobilized on chips after activation with EDC/NHS in 20
mM Na-acetate buffer (pH 4) for 20 min and remaining
active groups were deactivated with ethanolamine essen-
tially following the standard protocol of the supplier. Next,
purified HRV2 (¨20 Ag/ml) in 10 mM HEPES, 150 mM
NaCl, 2 mM CaCl2 (pH 7.4) was allowed to attach under a
flow rate of 5 Al/min resulting in immobilization of 300 to
500 resonance units (RU). To maximize the reproducibility,
care was taken to immobilize the same amount of virus for
each series of experiments. In the reference cell MBP alone
was immobilized on the chip using a pH of 4.5 during
coupling. The surface was regenerated with system buffer of
pH 2. This resulted in removal of eventually attached
receptor together with the virus. Thus, new virus had to be
bound prior to carrying out the next adsorption/desorption
measurement cycle.
NMR experiments
Measurements were carried out on a Bruker DRX 500
spectrometer equipped with a 5-mm inverse triple-resonance
probe head at 288 K. Samples were prepared in 500 AL 90%
H2O: 10% D2O buffer containing 150 mM NaCl, 8 mM
CaCl2, and 25 mM TRIS buffer (pH 7.5). The concentration
of the protein was 0.75 mM. Buffer was exchanged using a
PD10 column (receptor), and by ultrafiltration with a
Vivaspin (Vivascience) membrane with a cut-off value of
50 kDa (HRV2). Virus was mixed with the receptor to give a
final concentration of¨23 nM (¨500-fold excess of receptor
over the binding sites). One-dimensional STD NMR experi-
ments were recorded without spin-lock field because, due to
the natural broadening of the resonances from the virus
particles, no signals were observed. The suppression of the
strong water signal was carried out using the WATERGATE
sequence. Saturation was achieved by using a train of 40
selective Gaussian pulses with a duration of 49 ms and a
spacing of 1 ms. The relaxation delay was 1.5 s. Irradiation
was performed at 4 ppm for the on-resonance experiment,
while for the off resonance spectrum, the frequency was set
to 40 ppm. Subtraction of both spectra was performed
internally via phase cycling. The experimental conditions
were optimized by performing several 1D STD NMR control
experiments with different on-resonance frequencies with
the receptor sample in the absence of virus to verify that there
was no effect on the receptor resonances for an on resonance
frequency of 4 ppm. For the 1D NMR reference spectrum,
128 scans were recorded, and 8192 for the 1D STD NMR
spectrum with 4 and 16 dummy scans, respectively.Acknowledgments
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